Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 1/2007

01-03-2007 | ORIGINAL

The association between type 2 diabetes mellitus and A1/A2 polymorphism of glycoprotein IIIa gene

Authors: A. Kozieradzka, K. Kamiński, W. Pepiński, J. Janica, J. Korecki, B. Szepietowska, W. J. Musiał

Published in: Acta Diabetologica | Issue 1/2007

Login to get access
Metadata
Title
The association between type 2 diabetes mellitus and A1/A2 polymorphism of glycoprotein IIIa gene
Authors
A. Kozieradzka
K. Kamiński
W. Pepiński
J. Janica
J. Korecki
B. Szepietowska
W. J. Musiał
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Acta Diabetologica / Issue 1/2007
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-007-0238-6

Other articles of this Issue 1/2007

Acta Diabetologica 1/2007 Go to the issue

ORIGINAL

Effect of a variable hepatic insulin clearance on the postprandial insulin profile: insights from a model simulation study

ORIGINAL

Measurement of salivary adiponectin levels

ORIGINAL

Serum levels of sL-selectin and tumour necrosis factor-α in children with type 1 diabetes mellitus

ORIGINAL

Major childhood infectious diseases and other determinants associated with type 1 diabetes: a case-control study

ORIGINAL

M-cadherin, a candidate gene for type 2 diabetes and related phenotypes in a KK/Ta mouse model

ORIGINAL

Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits